Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects

Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects

Background Next-generation cancer immunotherapies aim to improve patient outcomes by combining inhibitory signal blockade with targeted T-cell costimulation in tumor and lymphoid tissues. Acasunlimab (DuoBody-PD-L1×4-1BB) is an investigational, bispecific antibody designed to elicit an antitumor imm...

Full description

Saved in:
Bibliographic Details
Main Authors: Maria Jure-Kunkel, Christina Yu, Nora Pencheva, Mark Fereshteh, Alexander Muik, Aras Toker, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Brandon W Higgs, Jordan M Blum, Saskia M Burm, Vanessa M Spires, Angelica Sette, Sina Fellermeier-Kopf, Andrea Imle, Michela Capello, Kristin Strumane, Theo Plantinga, Craig J Thalhauser, Kristina B Nürmberger, Patricia Garrido Castro, Carol Costa Sa, Bruna de Andrade Pereira
Format: Article
Language:English
Published: BMJ Publishing Group 2025-04-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/4/e011377.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/4/e011377.full

Similar Items